Failure of a Potent Cholecystokinin Antagonist to Protect Against Diet-Induced Pancreatitis in Mice
- 1 December 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 4 (6) , 739-743
- https://doi.org/10.1097/00006676-198912000-00013
Abstract
The effects of a potent cholecystokinin (CCK) receptor antagonist, L-364,718, on two forms of experimental acute pancreatitis in mice were evaluated. The antagonist prevented the hyperamylasemia, pancreatic edema, and acinar cell vacuolization that followed administration of a supramaximally stimulating dose of the cholecystokinin analogue cerulein. In contrast, the same dose of L-364,718 (1 mg/kg/6h) and an even higher dose (10 mglkg/6 h) failed to prevent the hyperamylasemia, acinar cell necrosis, and mortality that followed administration of a choline-deficient ethionine-supplemented diet. These observations are at variance with those previously reported to follow administration of the relatively weak cholecystokinin antagonist proglumide (Niederau C et al. J Clin Znvest 1986;78: 10.5643). The observations reported in this communication suggest that cholecystokinin does not play an important role in diet-induced pancreatitis and that CCK receptor antagonists are unlikely to be of benefit in the treatment of clinical acute pancreatitis.Keywords
This publication has 0 references indexed in Scilit: